[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Washington State University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":501},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,42,68,98,121,142,169,196,222,251,276,311,339,361,379,425,449,472],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100540975","phase-2-mirtazapine-for-the-treatment-of-methamphetamine-use-in-opioid-use-disorder-patients-receiving-medication-assisted-treatment-100540975",false,"NCT06323837","Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment","A Phase II Randomized, Double-blind, Placebo-controlled Clinical Trial (RCT) to Evaluate the Ability of Mirtazapine (MZP) to Increase Methamphetamine (MA) Abstinence Among Treatment-seeking Medication for Opioid Use Disorder (MOUD) Adults","MIRROM","Inclusion Criteria:\n\n* Enrollment at medication for opioid use disorder (MOUD) treatment at Oregon Recovery \\& Treatment Center\u002Fclinics in Spokane, WA.\n* Verification of a DSM-5104 diagnosis of an methamphetamine (MA) use disorder (i.e. mild, moderate, or severe),\n* Aged 18+ years,\n* Ability to provide written informed consent,\n* Demonstration of 78% adherence rate during the induction period and\n* Provision of at least one MA positive urinalysis at baseline or during induction.\n* Baseline complete blood cell count (CBC), total protein, albumin, glucose, alkaline phosphatase, creatinine, BUN, and electrolytes without clinically significant abnormalities as determined by clinician in conjunction with symptoms, physical exam, and medical history.\n* No current acute illness requiring prolonged medical care.\n* No serious chronic illnesses that are likely to progress clinically during trial participation.\n* Vital signs are within the normal ranges (i.e., Blood pressure: 90\u002F60 mm Hg to 120\u002F80 mm Hg; breathing: 12-18 breaths per minute; pulse: 60-100 beats per minute; temperature: 97.8 - 99.1 degrees Fahrenheit.\n\nExclusion Criteria:\n\n* Inability to demonstrate competency to provide informed consent because of cognitive or psychiatric disorders or limited English proficiency,\n* Prior diagnosis of dementia,\n* Medically or psychiatrically unsafe to participate as determined by Dr. Layton (Medical Director),\n* Documented suicide attempt in the past 30 days and\u002For serious suicide intention or plan as assessed by the Structured Clinical Interview for DSM-5 (SCID-5; clinical trials version)105\n* Suicide attempt in the last 2 years\n* Moderate or severe liver disease (AST, ALT, and total bilirubin \\>= 5 times upper limit of normal),\n* Impaired renal function (estimated GFR \\\u003C40 ml\u002Fmin),\n* Current severe cocaine, amphetamine, or alcohol use disorder as defined by DSM-5 criteria which Drs Layton and McPherson deem their participation as unsafe.\n* History of bipolar disorder or psychotic disorder, as determined by Structured Clinical Interview for DSM Disorders (SCID,\n* Currently taking 1) any type of opioid use disorder medication other than methadone or buprenorphine\u002Fnaloxone, or 2) phenytoin, carbamazepine, or another inducer of hepatic metabolism (such as rifampicin) and CYP enzyme inhibitor cimetidine.\n* Taking an anti-depressant medication within the past 30 days, including mirtazapine or a monoamine oxidase inhibitor,\n* Prescribed MZP in the least year, or\n* History of violent criminal behavior or being on parole,.\n* Currently pregnant or intending to become pregnant,.\n* Final determination of eligibility will be made by Dr. Layton in consultation with the PI.",true,"ALL","18 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This project will evaluate the ability of Mirtazapine (MZP), a pharmacologically unique medication with a growing body of evidence to support its efficacy and safety for the treatment of methamphetamine (MA) use among medication for opioid use disorder (MOUD) patients, to significantly decrease MA use and related health-impairing behaviors. MZP has already successfully been used in the treatment of methamphetamine (detailed further below and in the Appendices).\n\nThe investigators hypothesize that those assigned to the MZP plus treatment as usual (TAU) MZP+TAU arm will demonstrate significantly increased rates of biochemically verified abstinence from MA and other substances of abuse and experience improvements in health impairing behaviors relative to the placebo (PLO)+TAU arm across the 10-week treatment and follow-up periods.",[28],"Stimulant Use Disorder","RECRUITING","2026-07-01",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":33},"2024-06-17",{"date":37,"type":22},"2026-12-01",{"name":39,"class":40},"Washington State University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":51,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":41},"100453234","phase-2-pharmaceutically-enhanced-reinforcement-for-reduced-alcohol-and-smoking-100453234","NCT05181891","Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking","PERRAS","Inclusion Criteria:\n\n1. 4 or more standard drinks on the same occasion for women (5 or more standard drinks on the same occasion for men) on at least 4 occasions in the prior 30 days\n2. Seeking AUD treatment\n3. Seeking smoking cessation treatment\n4. Aged 18+ years\n5. DSM-5 diagnosis of AUD\n6. Currently smoking daily according to PhenX Smoking Status (100 or more lifetime cigarettes plus current daily smoking)\n7. Ability to read and speak English\n8. Ability to provide written informed consent\n9. Breath alcohol of 0.00 during informed consent\n10. Provision of at least 1 EtG-positive urine test at any time during the induction period and at least one COT-positive urine test at any time during the induction period; and\n11. Attended at least 4 of 6 possible visits during the induction period.\n\nExclusion Criteria:\n\n1. Significant risk of dangerous alcohol withdrawal, defined as a history of alcohol detoxification or seizure in the last 12 months and expression of concern by the participant about dangerous withdrawal\n2. Currently receiving any pharmacotherapy for alcohol\n3. Currently receiving any pharmacotherapy for smoking\n4. No suicide attempt in the last 20 years and\n5. Any other medical (discernable by initial blood tests) or psychiatric condition that Drs. Layton or Rodin determine would compromise safe participation.",{"count":50,"type":22},205,[25],"Using a randomized controlled trial (RCT), the goal of this study is to evaluate the ability of evidence based behavioral treatment (contingency management: CM) to significantly decrease alcohol use and cigarette smoking among treatment-seeking smokers with an alcohol use disorder (AUD) who have initiated pharmacotherapy (varenicline; VC) for smoking cessation.",[54,55],"Alcohol Use Disorder (AUD)","Nicotine Use Disorder",[57,58,59,60,55],"Alcohol Use Disorder","Contingency Management","Incentives for Sobriety","Varenicline","2026-06-30",{"date":32,"type":33},{"date":64,"type":33},"2022-07-11",{"date":66,"type":22},"2027-05-01",{"name":39,"class":40},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":17,"sex":18,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":41},"100569337","early-phase-1-effects-of-a-hemp-product-on-the-pharmacokinetics-and-pharmacodynamics-of-clopidogrel-100569337","NCT06692933","Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel","Inclusion Criteria:\n\n* 21-64 years old and healthy;\n* Confirmed by genetic test to be a CYP2C19 normal, rapid, or ultra-rapid metabolizer;\n* Not taking any medications (prescription and non-prescription, including clopidogrel) or dietary supplements\u002Fbotanical products known to alter the pharmacokinetics of cannabis and\u002For clopidogrel;\n* Have taken hemp or cannabis (in any form) before and tolerated it well;\n* Willing to abstain from consuming dietary supplements\u002Fbotanical products and citrus juices for the duration of the study;\n* Willing to abstain from cannabis\u002Fmarijuana, hemp, THC- and\u002For CBD-containing products for several weeks;\n* Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and morning of any inpatient day;\n* Willing to abstain from consuming alcoholic beverages for one day prior to any inpatient day;\n* Willing to use a secondary method of birth control that does not include the introduction or discontinuance of hormonal-based birth control (such as abstinence, copper IUD, or condoms), continuing for 1 week after completing the study;\n* Have the ability to and are willing to comply with the requirements of the study;\n* Geographically located within a 40-mile radius of Spokane and have the time to participate and;\n* Can read and speak English\n\nExclusion Criteria:\n\n* Under the age of 21 or over the age of 64;\n* Any major illness;\n* Pregnant or nursing;\n* History of allergy or intolerance to cannabis or clopidogrel;\n* Taking concomitant medications, both prescription and non-prescription (including clopidogrel) or dietary supplements\u002Fbotanical products known to alter the pharmacokinetics of cannabis and\u002For clopidogrel;\n* Never taken cannabis (in any form) before;\n* Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise participant safety or the quality of the data;\n* Currently using or have recently used drugs or other illicit substances for recreational purposes;\n* Have used cannabis\u002Fmarijuana, hemp, THC- and\u002For CBD-containing products within the last 4 weeks;\n* Have an out-of-range clinical laboratory value such that the study physician considers participation in the study a health risk, or;\n* Unable to read and speak English","21 Years","64 Years",{"count":77,"type":22},24,[79],"EARLY_PHASE1","The goal of this clinical trial is to determine how two different doses of cannabidiol (CBD), given as a hemp product, change the blood concentrations of the drug clopidogrel in the body. Results will be used to help design future studies and to assist healthcare providers in informing their patients about the safe use of CBD.",[82],"Interaction",[84,85,86,87,88,89],"CYP2C19","pharmacokinetics","hemp","CBD","natural product","clopidogrel","2026-06-02",{"date":92,"type":33},"2026-06-04",{"date":94,"type":33},"2024-06-20",{"date":96,"type":22},"2027-12-31",{"name":39,"class":40},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":75,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":41},"100569416","early-phase-1-evaluating-the-pharmacokinetics-of-oregano-and-potential-oregano-drug-interactions-using-a-drug-cocktail-approach-100569416","NCT06693960","Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach","Inclusion Criteria:\n\n* Between 18-64 years old and healthy\n* Not taking any medications (prescription and non-prescription) or dietary\u002Fherbal supplements that can interfere with study drug pharmacokinetics\n* Willing to abstain from consuming dietary\u002Fherbal supplements and citrus juices for several weeks\n* Willing to abstain from cannabis\u002Fmarijuana, hemp, and THC- and CBD-containing products for several weeks\n* Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and the morning of the first day of each study arm\n* Willing to abstain from consuming any alcoholic beverages for at least 1 day prior to any study day and during the study day\n* Willing to use a secondary method of birth control that does not include the introduction or discontinuance of hormonal-based birth control (such as abstinence, copper IUD, or condoms). Specifically, regardless of the use hormonal-based birth control, a non-hormonal method should be used for the duration of the study and for three weeks following cessation of participation.\n* Willing to abstain from consuming oregano (as a food additive or otherwise) for the duration of the study\n* Geographically located within a 40-mile radius of Spokane and have the time to participate\n\nExclusion Criteria:\n\n* Under 18 or over 64 years old\n* Taking medications or dietary\u002Fherbal supplements that can interfere with study drug pharmacokinetics\n* Have a major illness\n* Taking medication\u002Fsupplements for a mineral deficiency\n* History of intolerance or allergy to oregano or any of the cocktail drugs (caffeine, dextromethorphan, losartan, midazolam, and omeprazole)\n* Use of cannabis\u002Fmarijuana, hemp, and CBD- and\u002For THC-containing products within the last month\n* Currently using drugs or illicit substances for recreational purposes\n* Pregnant or nursing\n* Geographically located outside the 40-mile radius of Spokane and do not have the time to participate\n* Cannot read and speak English",{"count":105,"type":22},16,[79],"The purpose of this clinical trial is to determine how the supplement oregano affects how the body metabolizes pharmaceutical drugs.",[82],[85,110,111,112,113,114],"drug interaction","natural products","oregano","cytochrome P450","cocktail",{"date":92,"type":33},{"date":117,"type":33},"2024-09-26",{"date":119,"type":22},"2027-01-31",{"name":39,"class":40},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":132,"conditions":133,"keywords":134,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":41},"100520195","early-phase-1-contribution-of-ugt2b17-to-the-pharmacokinetics-of-diclofenac-100520195","NCT06053411","Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac","Pilot Study to Assess the Contribution of UGT2B17 and Associated Genetic Polymorphisms on the Pharmacokinetics of Diclofenac Alone and Upon Co-administration With Curcumin","Inclusion Criteria:\n\n* Aged from 18-64 years and healthy\n* Not taking any medications (prescription and non-prescription) or dietary\u002Fherbal supplements known to alter the pharmacokinetics of diclofenac or curcumin\n* Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and morning of the first day of each study arm\n* Willing to abstain from consuming any alcoholic beverages for one day prior to any study day, during the 14-hour inpatient days, and for the outpatient visit(s) following the 14-hour days\n* Willing to use a secondary method of birth control that does not include the introduction or discontinuance of hormonal-based birth control (such as abstinence, copper IUD, or condoms)\n* Have the time to participate\n* Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for the subject to comply with the requirements of the study\n\nExclusion Criteria:\n\n* Under the age of 18 or over the age of 65 years\n* Smoke\u002Fvape\u002Fchew tobacco products\n* Use cannabis products, including marijuana, hemp, and other THC- or CBD-containing products\n* Have any current major illness or chronic illness such as (but not limited to) kidney disease, hepatic disease, diabetes mellitus, hypertension, coronary artery disease, chronic obstructive pulmonary disease, cancer, or HIV\u002FAIDS\n* History of anemia or any other significant hematologic disorder\n* History of drug or alcohol addiction or major psychiatric illness\n* Pregnant or nursing or plan to become pregnant within 3 weeks after participation\n* History of allergy intolerance to diclofenac or curcumin\n* Taking concomitant medications, both prescription and non-prescription (including dietary supplements\u002Fherbal products), known to alter the pharmacokinetics of diclofenac or curcumin\n* Taking any turmeric spice or curcumin supplement\n* Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise participant safety or quality of the data\n* Out-of-range clinical laboratory value that the study physician considers participation in the study a health risk","65 Years",{"count":130,"type":22},30,[79],"The purpose of this pilot study is to gather preliminary data on the (1) contribution of the understudied drug metabolizing enzyme, UDP-glucuronosyltransferase (UGT) 2B17, to the metabolism of a widely used medication, diclofenac, and (2) impact of the UGT2B17 inhibitor and natural product, curcumin, on diclofenac pharmacokinetics. Results will inform future studies aimed to assess the effects of UGT2B17 genetic polymorphisms and co-consumed xenobiotics on the pharmacokinetics and toxicity risk of diclofenac and other UGT2B17 drug substrates.",[82],[135],"Pharmacokinetic",{"date":92,"type":33},{"date":138,"type":33},"2024-03-01",{"date":140,"type":22},"2026-12-18",{"name":39,"class":40},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":17,"sex":18,"minAge":74,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":168,"locationsCount":41},"100504295","early-phase-1-evaluating-a-potential-pharmacokinetic-kratom-oxycodone-interaction-concurrent-with-clinical-endpoints-100504295","NCT05846451","Evaluating a Potential Pharmacokinetic Kratom-oxycodone Interaction Concurrent With Clinical Endpoints","Inclusion Criteria:\n\n* Males and females, aged from 21-45 years and healthy\n* Body weight between 130 and 250 pounds (60-115 kg) and body mass index between 19 and 30\n* Not taking any medications (prescription and non-prescription) or dietary supplements\u002Fbotanical products known to alter the pharmacokinetics of either oxycodone or kratom\n* Willing to abstain from consuming dietary supplements\u002Fbotanical products and fruit juices for several weeks\n* Willing to abstain from cannabis\u002Fmarijuana, hemp, and THC- and\u002For CBD-containing products for several weeks\n* Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and morning of any inpatient visit\n* Willing to abstain from consuming alcoholic beverages for one day prior to any inpatient visit\n* Willing to use an additional method of contraception that does not include oral contraceptive pills, patches, or other hormonal methods (such as abstinence, copper IUD, or condoms)\n* Have consumed kratom previously and tolerated it well without any unpleasant effects\n* Willing to abstain from kratom for several weeks\n* Have consumed any opioid previously and tolerated it well without any unpleasant effects or addiction\n* Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for the subject to comply with the requirements of the study\n* Geographically located within a 40-mile radius of Spokane and have the time to participate\n\nExclusion Criteria:\n\n* Males and females under the age of 21 or over the age of 45\n* People who weigh less than 130 pounds or more than 250 pounds\n* People with a body mass index less than 19 or greater than 30\n* Any current major illness or chronic illness including but not limited to kidney disease, hepatic disease, diabetes mellitus, hypertension, coronary artery disease, chronic obstructive pulmonary disease, cancer, or HIV\u002FAIDS\n* No previous exposure to kratom\n* No previous exposure to an opioid\n* History of anemia or any other significant hematologic disorder\n* History of substance abuse, dependence, or addiction or major psychiatric illness\n* A need for chronic opioid analgesics\n* Use of opioid analgesics 3 weeks prior to initiation of the study\n* An imminent likely need for opioid analgesics (e.g., planned dental or surgical procedure)\n* Pregnant or nursing\n* History of allergy or intolerance to kratom, other opioids, or oxycodone\n* Taking concomitant medications, both prescription and non-prescription (including dietary supplements\u002Fbotanical products), known to alter the pharmacokinetics of kratom or oxycodone\n* Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data\n* History of sleep apnea\n* Any prior use of amphetamines, benzodiazepines, cocaine, MDMA, opioids, PCP, or other drugs for recreational purposes\n* Use of cannabis\u002Fmarijuana, hemp, THC-containing products, CBD-containing products, or CBD within the last month\n* Out-of-range clinical laboratory value that the study physician considers participation in the study a health risk\n* Inability to speak, read, and understand English","45 Years",{"count":105,"type":22},[79],"The goal of this study is to investigate whether the botanical product kratom affects how the body processes the opioid drug oxycodone. The main research questions to be answered are two-fold:\n\n1. How does kratom affect the manner in which oxycodone is metabolized (broken down and removed) by the body?\n2. Does kratom change the effects oxycodone exerts on the body?\n\nHealthy adult participants will complete four study arms, during which they will be given the following:\n\n* Kratom (as a tea)\n* A single dose of oxycodone (as a tablet)\n* Kratom tea and a single dose of oxycodone\n* Kratom tea for four days, then kratom tea and a single dose of oxycodone",[153],"Herbal Interaction",[155,85,156,157,158,159,88,160,161,162],"pharmacokinetic","pharmacodynamic","pharmacodynamics","kratom","oxycodone","botanical product","natural product-drug interaction","mitragynine",{"date":164,"type":33},"2026-06-03",{"date":166,"type":33},"2023-06-01",{"date":37,"type":22},{"name":39,"class":40},{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":17,"sex":18,"minAge":74,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":23,"phases":177,"briefSummary":178,"conditions":179,"keywords":181,"overallStatus":187,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":41},"100615766","phase-2-acute-effects-of-cannabis-on-cognition-and-affect-100615766","NCT07296874","Acute Effects of Cannabis on Cognition and Affect","Inclusion Criteria:\n\n* be 21 years of age or older\n* be fluent in English\n* use of cannabis at least once a week for at least one year\n* inhalation as their typical method of administration\n* be willing to abstain from cannabis on the day of their scheduled testing session\n\nExclusion Criteria:\n\n* neurological conditions (e.g., neurodegenerative disorders, severe head injury, multiple concussions)\n* serious psychiatric conditions (e.g., psychosis, bipolar disorder)\n* family history of psychosis\n* intellectual disabilities or learning disorders (e.g., dyslexia)\n* chronic medical conditions that affect cognition or increase risk of cannabis use or exposure to cold water (e.g., heart disease, diabetes, Reynaud's disease, history of frostbite, peripheral neuropathy, history of fainting or seizures, fractures or wounds on both hands or wrists),\n* heart disease\n* BMI \\> 34\n* pregnant or lactating\n* use of illicit drugs in past 6 months\n* heavy use of alcohol (drinking \\>4 drinks \\>4 times per week)\n* nicotine\u002Ftobacco use\n* have experienced a severe adverse reaction to cannabis (e.g., panic attack, psychosis)",{"count":176,"type":22},90,[25],"This study will examine how a moderate dose of THC affects mood, stress responses, and cognitive functioning in regular cannabis users. The study uses a double-blind, placebo-controlled, crossover design, meaning each participant will complete two sessions. Specifically, each participant will be given active cannabis (20 mg THC) in one session, and placebo in the other session. The order will be randomized across participants, so half will receive cannabis first, and the other half will receive placebo first.\n\nNinety adults who use cannabis at least weekly will be recruited from the local community. After an online screening survey, eligible participants will attend a laboratory visit where the participants will provide informed consent and complete saliva and urine drug tests to confirm recent abstinence from cannabis and absence of other drugs. Participants who pass screening will complete baseline questionnaires of cannabis use patterns, depression, anxiety, ADHD symptoms, emotion regulation, affect, and demographic information.\n\nCannabis and placebo materials (obtained from NIDA) will be vaporized using a Volcano vaporizer device. Participants will inhale the vapor under supervision, and neither the participant nor the researcher assessing outcomes will know which product is administered. After vaping, participants will complete repeated mood ratings, saliva samples, and a battery of cognitive tests assessing executive functions like planning, inhibition, working memory, and cognitive flexibility.\n\nParticipants will also complete a standardized stress challenge (the Maastricht Acute Stress Test), which involves repeated trials of placing their hand in cold water and doing challenging mental math, followed by additional mood ratings and saliva samples. The participants will then watch a nature video and report their feelings of awe and affect.\n\nAt the end of each session, participants will remain in a supervised room with entertainment and snacks until at least four hours have passed since vaping and the participants report feeling sober. The participants will then return for a second session with the opposite study condition (THC or placebo) one week later. Both sessions follow the same procedures. Participants are fully debriefed after completing the study.",[180],"Cannabis Use",[182,183,184,185,186],"Cannabis","THC","Executive functioning","Stress reactivity","Affect","NOT_YET_RECRUITING","2026-05-28",{"date":190,"type":33},"2026-06-01",{"date":192,"type":22},"2026-07",{"date":194,"type":22},"2028-05",{"name":39,"class":40},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":23,"phases":205,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":41},"100606116","tms-to-improve-recovery-outcomes-among-patients-with-opioid-use-disorder-oud-and-alcohol-use-disorder-aud-100606116","NCT07171359","TMS to Improve Recovery Outcomes Among Patients With Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD)","Transcranial Magnetic Stimulation (TMS) to Improve Recovery Outcomes Among Patients With Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD)","TMS4OUDAUD","Inclusion Criteria:\n\n* 18+ years old\n* Enrolled in the Intensive Outpatient Program at Another Chance Drug \\& Alcohol Rehab Center of Portland, Portland, OR.\n* Diagnosed with Opioid Use Disorder\n* Diagnosed with Alcohol Use Disorder\n\nExclusion Criteria:\n\n* Children \\\u003C18 years old\n* Pregnant\n* Non-English speaking\n* Currently taking prescription benzodiazepines or anti-convulsive medications\n* In active alcohol or opioid withdrawal\n* History of seizure disorder diagnosis\n* History of Schizophrenia, Bipolar Disorder, Mania",{"count":21,"type":22},[206],"NA","The study aims to explore the potential of Transcranial Magnetic Stimulation (TMS), particularly Theta Burst Stimulation (TBS), as an adjunctive treatment to enhance recovery outcomes (consumption and craving; withdrawal symptoms; mental, physical, sleep, and cognitive health; engagement with therapy, etc.) in individuals with Opioid Use Disorder (OUD) and individuals with Alcohol Use Disorder (AUD). This project will be completed in partnership with Another Chance Rehab (Portland): Portland's top addiction treatment program offering evidence-based treatment programs for a range of substance use disorders. Another Chance Rehab will serve as the project site for this work.",[57,209],"Opioid Use Disorder",[211,209,57,212,213],"Transcranial Magnetic Stimulation","Intensive Outpatient Treatment","Theta Burst Stimulation","2026-05-26",{"date":216,"type":33},"2026-05-29",{"date":218,"type":22},"2027-06-01",{"date":220,"type":22},"2027-10-01",{"name":39,"class":40},{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":148,"enrollmentInfo":228,"targetDuration":4,"studyType":23,"phases":230,"briefSummary":232,"conditions":233,"keywords":238,"overallStatus":187,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":248,"leadSponsor":250,"locationsCount":41},"100630931","phase-4-sleep-loss-and-circadian-misalignment---mechanisms-of-insulin-resistance-100630931","NCT07494084","Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance","Inclusion Criteria:\n\n1. Must be between 18-45 years old.\n2. Has a BMI of 18-25 kg\u002Fm2 stable weight over the previous 6 weeks.\n3. Is physically and psychologically healthy (incl. regular menstrual cycles in women, no clinical disorders and\u002For illnesses). Women will be studied during the follicular phase of their menstrual cycle.\n\n   Menstrual cycle criteria (using PMID 10941950) 18 to 25 years - Cycle variation ≤9 days 26 to 41 years - Cycle variation ≤7 days 42 to 45 years - Cycle variation ≤9 days\n4. No current medical or drug treatment (to include steroids or hormones of any type including contraceptives), as assessed by questionnaire.\n5. Has a negative pregnancy test (women), no clinically significant abnormalities in blood and urine, and free of traces of drugs.\n6. No history of clinically relevant psychiatric illness.\n7. No previous history of drug or alcohol abuse.\n8. Not a current smoker.\n9. No history of brain injury or of learning disability.\n10. No previous adverse reaction to sleep deprivation, jet lag, shift work or any of the drugs to be administered.\n11. Not vision or hearing impairment unless corrected back to normal.\n12. No endocrine disorder (no abnormal thyroid function tests; no abnormal morning blood cortisol; no primary gonadal disease as indicated by serum LH or FSH concentration \\> 10 or \\> 15 IU\u002FL, respectively; and no hyperprolactinemia indicated by prolactin \\> 25 μg\u002FL).\n13. No sleep or circadian disorder.\n14. Has good habitual sleep with regular bedtimes (between 6 and 10 hours in duration).\n15. Not extreme morning- nor extreme evening-type using Horne-Ostberg Morningness-Eveningness criteria.\n16. No travel across time zones within one month of entering the study.\n17. No shift work within three months of entering the study.\n18. No anemia (hematocrit \\\u003C38% in men, \\\u003C34% in women).\n19. No blood donation within the previous 8 weeks.\n20. No concurrent participation in another research study.",{"count":229,"type":22},48,[231],"PHASE4","The purpose of this study is to examine the impact of timed cortisol release or differently timed cortisol rhythms on insulin resistance in both men and women undergoing sleep restriction. Chronic sleep loss is highly prevalent, affecting 1 in 3 adults in the US. Chronic sleep loss causes stress which induces insulin resistance and leads to obesity and type 2 diabetes. Many factors contribute to sleep loss including shift work, environmental disturbances, sleep\u002Fcircadian disorders and comorbid medical and mental health conditions. Sleep loss increases the stress hormone cortisol in the evening and decreases daytime testosterone. Examining these hormones in a controlled laboratory environment under different sleep schedules may help researchers find solutions for adults experiencing negative health consequences related to chronic sleep loss.",[234,235,236,237],"Shift Work Schedule","Circadian Rhythm","Insulin Resistance","Circadian Misalignment",[239,240,241,242,243],"Shift work","insulin resistance","sleep","circadian rhythm","type 2 diabetes","2026-05-12",{"date":246,"type":33},"2026-05-15",{"date":30,"type":22},{"date":249,"type":22},"2029-07",{"name":39,"class":40},{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":23,"phases":261,"briefSummary":262,"conditions":263,"keywords":264,"overallStatus":187,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":273,"leadSponsor":275,"locationsCount":4},"100599726","testing-a-music-listening-mhealth-intervention-for-stress-reduction-in-early-recovery-calmify-ii-100599726","NCT07088237","Testing a Music Listening mHealth Intervention for Stress Reduction in Early Recovery (CalmiFy II)","Testing a Music Listening mHealth Intervention for Stress Reduction in Early Recovery","CalmiFy II","Inclusion Criteria:\n\n* Subject can and has signed an Institutional Review Board (IRB) approved informed consent form (ICF).\n* Age ≥18 and ≤35 years.\n* In early-stage recovery for alcohol use (within 12 months)\n* Own a smartphone with a data plan\n* Not experiencing symptoms of severe depression\n* Not experiencing thoughts of suicide\n* Meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for alcohol use disorder (AUD)\n* Not currently taking medication treatment for opioid use disorder (OUD)\n* Able to speak and read English\n\nExclusion Criteria:\n\n* Currently experiencing symptoms of severe depression\n* Currently experiencing thoughts of suicide\n* Currently taking medication treatment for opioid use disorder (OUD)\n* Are unable to provide voluntary informed consent.\n* Cannot read or speak English.","35 Years",{"count":130,"type":22},[206],"The overarching goal of this study is to develop and examine the feasibility of a music-listening intervention that can be deployed in \"real time\" to regulate emotions and reduce momentary stress among young adults within the first 12 months of recovery from alcohol use disorder. The investigators design the study with two phases to address three aims: Phase I includes the first two aims. For Aim 1, the investigators will conduct formative research with a sample of young adults who have are within 12 months of recovery (N = 30) to identify features of music selections that are most effective in reducing momentary stress in real-world, ambulatory settings. For Aim 2, the investigtors will focus on developing mobile health technology that uses passive sensing and machine learning to automatically predict moments of heightened stress in real-time and suggest specific musical selections when stress is detected. During Phase II (Aim 3), the investigators will test the feasibility of a novel music-listening intervention among a second unique sample of young adults who are within 12 months of recovery from AUD (N = 30). This protocol refers only to Phase II of the larger study.",[54],[265,266,267,268],"recovery","alcohol use disorder","stress","music listening","2026-04-29",{"date":271,"type":33},"2026-05-05",{"date":37,"type":22},{"date":274,"type":22},"2028-03-01",{"name":39,"class":40},{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":280,"acronym":4,"eligibilityCriteria":281,"healthyVolunteers":17,"sex":282,"minAge":283,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":288,"conditions":289,"keywords":292,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":41},"100623210","phase-2-effects-of-hemp-derived-cannabinoids-on-menopause-symptoms-100623210","NCT07393672","Effects of Hemp-Derived Cannabinoids on Menopause Symptoms","Inclusion Criteria:\n\n* designated female at birth\n* 40-60 years of age\n* able to give informed consent (no intellectual disability)\n* stable pharmacotherapeutic regimen, no change in the past 3 months\n* abstinent from regular cannabis use (\\\u003C1x\u002Fmonth) for past year, and willing to abstain from use for 3 months\n* abstinent for supplements, don't add any supplements (no changes in past 3 months)\n* own a smartphone\n* have access to Zoom on a secure, stable internet connection\n* perimenopausal or menopausal\n\nExclusion Criteria:\n\n* currently taking anti-depressant, anti-anxiety, and\u002For antipsychotic medication\n\n  * severe depression, neurovegetative symptoms, or current suicidality\n  * psychosis or family history of psychosis\n  * pregnant or breastfeeding\n  * chemotherapy\n  * hypotension\n  * drug testing for work or other reasons\n  * illicit drug use in past 3 months (cannabis not illicit)\n  * heavy alcohol use (4 drinks more than 4x\u002Fweek)\n  * international\u002Fair travel planned for more than one week in the next 3 months\n  * cocounut allergy","FEMALE","40 Years","60 Years",{"count":286,"type":22},104,[25],"The purpose of the study is to examine the impact of hemp-derived minor cannabinoids on symptoms of menopause\u002Fperimenopause.",[290,291],"Menopause","Perimenopause",[290,291,293,294,87,295,296,297,298,299,300,301,302],"Cannabinoids","CBG","Hemp-derived THC","Cognition","Anxiety","Sleep","Mood","Pain","Stress","Brain fog","2026-03-06",{"date":305,"type":33},"2026-03-10",{"date":307,"type":33},"2026-02-11",{"date":309,"type":22},"2026-11-10",{"name":39,"class":40},{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":23,"phases":321,"briefSummary":322,"conditions":323,"keywords":326,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":338},"100588719","family-engagement-strategy-for-coordinated-specialty-care-100588719","NCT06945055","FAmily Engagement Strategy for Coordinated Specialty Care","Integration of a Culturally Responsive Family Peer Delivered Engagement Strategy in Coordinated Specialty Care","FAMES","Family Member \u002F Support Person Inclusion Criteria:\n\n* Family member\u002Fsupport person of an individual enrolled in coordinated specialty care services for less than or equal to 6 months.\n* 18 years of age or older.\n* During the active implementation period (FAMES) did not participate in the attention control condition.\n\nExclusion Criteria:\n\n* If they do not understand the consent process.\n* If they do not speak and\u002For understand English or Spanish.\n\nPrimary Service User Inclusion Criteria\n\n* enrolled in coordinated specialty care services for less than or equal to 6 months.\n* 15 years of age or older.\n* Has a family member\u002Fsupport person willing to engage in the study. during the active implementation period (FAMES) did not participate in the attention control condition.\n\nExclusion Criteria\n\n* if they do not understand the consent process\n* If they do not speak and\u002For understand English or Spanish",{"count":320,"type":22},900,[206],"Family members\u002Fsupport persons' engagement in mental health services has been linked to reduced burden and stress and improves engagement and outcomes in individuals in the early stages of psychosis. The goal of FAMES is to address low family member\u002Fsupport person engagement in services. FAMES will also address disparities in coordinated specialty care (CSC) by using a culturally responsive family engagement strategy to be delivered by family peers.",[324,325],"Family Members","Implementation",[327,328,329],"early psychosis","family peer","engagement","2026-02-19",{"date":332,"type":33},"2026-02-23",{"date":334,"type":33},"2025-03-01",{"date":336,"type":22},"2029-12",{"name":39,"class":40},4,{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":18,"minAge":283,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":23,"phases":349,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":360,"locationsCount":41},"100533573","cognition-after-osa-treatment-among-native-american-people-catnap-100533573","NCT06227572","Cognition After OSA Treatment Among Native American People (CATNAP)","Cognition After Obstructive Sleep Apnea (OSA) Treatment Among Native American People (CATNAP)","CATNAP","Inclusion Criteria:\n\n* Age 50 years and older\n* Self report American Indian or Alaskan Native\n* diagnosed with obstructive sleep apnea\n* prescribed PAP therapy and have a device\n* \\*Ability to understand written and spoken English; and\n* \\*Ability and willingness to follow all study protocols.\n\nExclusion Criteria:\n\n* Living in a household with someone who is enrolled in the study\n* Already using PAP device at Medicaid recommended standards\n* Cognitive decline, unable to consent on their own",{"count":348,"type":22},140,[206],"This research project will develop and implement a motivational interviewing and electronic messaging intervention to address obstructive sleep apnea (OSA), positive airway pressure (PAP) adherence, and risk of Alzheimer's disease and related dementias in American Indians. The project will work with American Indian Elders, aged 50 years and older, from three Northern Plains Reservations and surrounding communities. A total of 300 American Indian elders with a confirmed OSA diagnosis and prescribed PAP therapy will be randomized to receive usual care consisting of PAP therapy alone (control condition) or usual care plus the culturally informed CATNAP MI component (intervention condition).",[352,353],"Obstructive Sleep Apnea","Cognitive Change","2026-01-07",{"date":356,"type":33},"2026-01-09",{"date":358,"type":33},"2025-02-06",{"date":96,"type":22},{"name":39,"class":40},{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":365,"acronym":366,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":259,"enrollmentInfo":367,"targetDuration":4,"studyType":368,"phases":4,"briefSummary":369,"conditions":370,"keywords":371,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":378,"locationsCount":41},"100596964","developing-a-music-listening-mhealth-intervention-for-stress-reduction-in-early-recovery-100596964","NCT07052318","Developing a Music Listening mHealth Intervention for Stress Reduction in Early Recovery","CalmiFy",{"count":130,"type":22},"OBSERVATIONAL","The overarching goal of this study is to develop and examine the feasibility of a music-listening intervention that can be deployed in \"real time\" to regulate emotions and reduce momentary stress among young adults within the first 12 months of recovery from alcohol use disorder. We design the study with two phases to address three aims: Phase I includes the first two aims. For Aim 1, we will conduct formative research with a sample of young adults (N = 30) who have are within 12 months of recovery to identify features of music selections that are most effective in reducing momentary stress in real-world, ambulatory settings. For Aim 2, we will focus on developing mobile health technology that uses passive sensing and machine learning to automatically predict moments of heightened stress in real-time and suggest specific musical selections when stress is detected. During Phase II (Aim 3), we will test the feasibility of a novel music-listening intervention among a second unique sample of young adults who are within 12 months of recovery from AUD (N = 30). This protocol refers only to Phase I of the larger study, which focuses on observing music listening preferences and physiological and mental stress among people in early recovery from alcohol use disorder.",[54],[265,266,267,268],"2025-07-18",{"date":374,"type":33},"2025-07-23",{"date":376,"type":33},"2025-05-19",{"date":61,"type":22},{"name":39,"class":40},{"id":380,"slug":381,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":23,"phases":389,"briefSummary":390,"conditions":391,"keywords":395,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":41},"100536490","virtual-incentive-treatment-for-alcohol-100536490","NCT06265506","Virtual Incentive Treatment for Alcohol","Assessing the Clinical and Cost-Effectiveness of a Virtual PEth-based Contingency Management for Adults With AUD","VITA","Inclusion Criteria:\n\n1. Had 2 heavy drinking episodes (assigned male at birth \\> 4 standard drinks (SDs), assigned female at birth \\> 3 SDs) or ≥14 SDs in the prior 14 days verified by PEth 16:0\u002F18:1 biomarker \\> 20 ng\u002FmL (indicates at least 2 heavy drinking episodes in past two weeks);\n2. Have a DSM-5 diagnosis of a current AUD as assessed by the Structured Clinical Interview for DSM-5;\n3. 18+ (individuals over 65 will be assessed for cognitive impairments)\n4. Are not receiving treatment for AUD\n5. Are able to complete virtual study visits via Zoom\n\nExclusion Criteria:\n\n1. have a current diagnosis of severe substance use disorder (other than AUD, tobacco, and cannabis);\n2. PEth biomarker ≤ 20 ng\u002FmL (indicates no heavy drinking in past month)\n3. inability to provide informed consent based on the UBACC or MacCAT-CR;\n4. alcohol withdrawal-related seizure or hospitalization in prior 12 months;\n5. psychiatrically or medically unsafe to participate, as assessed by the PI; and\u002For\n6. currently enrolled in alcohol treatment or another alcohol treatment study.",{"count":388,"type":22},200,[206],"The overall objective of this program of research is to utilize phosphatidylethanol (PEth), a blood-based biomarker that can detect alcohol use for up to 28 days to deliver a feasible telehealth-based 26-week CM intervention. This study will test a telehealth PEth-based CM model in a sample of adults with AUD (n=200), recruited via online platforms by randomizing individuals to six months of 1) an online cognitive behavioral therapy for AUD (CBT4CBT) and telehealth PEth-based CM (CM condition) or 2) CBT4CBT and reinforcers for submitting blood samples (no abstinence required) (control condition). Investigators will assess group differences in PEth-defined abstinence and regular excessive drinking (PEth \\>= 200 ng\u002FmL), and alcohol-related harms (e.g., smoking, drug use). This study will address important gaps in CM research by assessing outcomes during a 12-month follow-up, which is much longer than most previous CM studies; using a conceptual model to identify predictors of post-treatment abstinence. Investigators will conduct an economic analysis to place the cost of this model in the context of downstream CM-associated cost-offsets and improvements in personal and public health.",[57,392,393,394],"Alcohol Drinking","Alcohol Abuse","Alcohol Dependence",[58,396,397,398,399,400,401,402,403,404,405,406,296,407,408,409,410,411,412,413,414,415,416],"Alcohol Abstinence","Adult","Biological Markers","Blood","Clinical effectiveness","Cognitive Therapy","Blood collection","Ethyl glucuronide","Health Care Costs","Heavy Drinking","Addictions Neuroclinical Assessment","Incentives","Phosphatidylethanol","Incentive salience","Anhedonia","Longitudinal Studies","Prediction of Response to Therapy","Randomized Clinical Trial","Telehealth","Virtual Health","Video conference","2025-05-23",{"date":419,"type":33},"2025-05-30",{"date":421,"type":33},"2024-06-18",{"date":423,"type":22},"2028-04-04",{"name":39,"class":40},{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":23,"phases":434,"briefSummary":435,"conditions":436,"keywords":437,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":41},"100461137","family-peer-navigator-for-early-psychosis-for-black-families-100461137","NCT05284721","Family Peer Navigator for Early Psychosis for Black Families","A Family Peer Navigator Model to Increase Access and Initial Engagement in Coordinated Specialty Care Programs Among Black Families","Inclusion Criteria:\n\n1. ≥ 18 years of age\n2. Identifies as Black\u002FAfrican American\n3. Loved one who meets criteria for risk of psychosis with a total score of ≥ 3 on the Prodromal Questionnaire- Brief Version\n\nExclusion Criteria:\n\n1. Family members who cannot understand the consent process\n2. Non-English speaking adults\n3. Black\u002FAfrican American families referred to coordinated specialty care and who have already been determined eligible for services by providers.",{"count":433,"type":22},50,[206],"Building upon formative research, this mixed methods study will be conducted in three phases to develop, refine, and pilot-test a multi-component Family Peer Navigator model designed to increase access to and initial engagement in coordinated specialty care for early psychosis among Black\u002FAfrican American families.",[324],[438,439,440],"Black\u002FAfrican American","Early Psychosis","Access and Engagement","2025-04-17",{"date":443,"type":33},"2025-04-23",{"date":445,"type":33},"2023-01-01",{"date":447,"type":22},"2025-09-30",{"name":39,"class":40},{"id":450,"slug":451,"hasResults":11,"nctId":452,"briefTitle":453,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":23,"phases":458,"briefSummary":459,"conditions":460,"keywords":462,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":41},"100546622","indian-transforming-alzheimers-care-training-intact-100546622","NCT06397339","Indian Transforming Alzheimer's Care Training (INTACT)","INTACT","CLINIC Eligibility criteria\n\nTo be eligible to participate in INTACT a clinic must be:\n\n1. A primary care clinic\n2. Have at least 20 AI\u002FAN active patients 55 years or older\n3. Have an EHR system\n4. Not intending to change EHR systems in the next year\n5. Willing to conduct a total of 40 limited patient chart reviews to assess quality of care metrics for AI\u002FAN patients with MCI and ADRD, staff permitting\n\nPCP\n\nEligibility criteria:\n\nTo be eligible to participate in the baseline and follow-up surveys a primary care provider must be:\n\n1. have a title of MD, DO, Nurse Practitioner, or PA, and\n2. regularly provides care to AI\u002FANs aged 65 and older.\n\nPATIENTS\n\nWe will only collect patient EHR data from eligible patients who:\n\n1. Recorded as AI\u002FAN in the EHR system\n2. Active clinic patient with prevalent ADRD as of the first day of the time period each data extraction will cover\n3. Age 55 or older at the start of the surveillance interval\n4. At least one primary care clinic visit during the time period each data extraction will cover.\n\nThere are no exclusion criteria for the clinic, PCPs and patients.",{"count":457,"type":22},28,[206],"INTACT will utilize a group-randomized trial, to test the effectiveness of a culturally informed provider training and \"dementia friendly clinic\" intervention for detection and appropriate management of AI\u002FAN patients with ADRD and MCI in 28 urban and rural clinics serving AI\u002FANs.",[461],"Alzheimer Disease",[463],"ADRD, MCI","2024-08-14",{"date":466,"type":33},"2024-08-19",{"date":468,"type":33},"2022-10-05",{"date":470,"type":22},"2026-04-30",{"name":39,"class":40},{"id":473,"slug":474,"hasResults":11,"nctId":475,"briefTitle":476,"officialTitle":476,"acronym":477,"eligibilityCriteria":478,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":479,"enrollmentInfo":480,"targetDuration":4,"studyType":23,"phases":482,"briefSummary":483,"conditions":484,"keywords":485,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":41},"100551193","automated-reinforcement-management-systems-phase-ii-100551193","NCT06456905","Automated Reinforcement Management Systems, Phase II","ARMS II","Inclusion Criteria:\n\n* Age 18-70 years\n* Have consumed 3 or more drinks in once occasion 4 or more times in the previous 30 days 3\n* Have the ability to read and speak English\n* Have the ability to provide written informed consent\n* Have a breath alcohol value of 0.00 during informed consent\n* Owns a smartphone with an active service provider that is compatible with the study application.\n\nExclusion Criteria:\n\n* Severe alcohol use disorder that our medical staff deems too risky for safe participation;\n* Significant risk of dangerous alcohol withdrawal, defined as history of seizure due to alcohol withdrawal in the last 12 months and\u002For expression of concern by the participant about dangerous withdrawal\n* Anyone aged 71 or older.\n* Anyone with a suicide attempt in the last 2 years.\n* Individuals who express concern regarding dangerous withdrawal or who exhibit dangerous withdrawal symptoms.\n* Individuals who do not test BrAC = 0.00 on the breathalyzer during the baseline visit.\n* Any other condition that investigators determine a medical or psychiatric condition that would compromise safe study participation.","70 Years",{"count":481,"type":22},125,[206],"The Automated Reinforcement Management Systems Phase II (ARMS II) study is a phase II trial is a randomized controlled, non-medicated assisted trial to determine the effectiveness of Contingency Management (CM) treatment for reducing alcohol drinking among adults who want to quit or reduce their alcohol consumption.",[57],[486,487,488,489,490,491,492],"alcohol consumption","contingency management","alcohol dependency","positive reinforcement","remote treatment","non-medicated assisted treatment","alcohol studies","2024-08-09",{"date":495,"type":33},"2024-08-13",{"date":497,"type":33},"2024-06-07",{"date":499,"type":22},"2025-09-01",{"name":39,"class":40},""]